长期低剂量非那雄胺与良性前列腺增生及前列腺癌风险的关系
本研究为倾向性匹配的回顾性队列研究,纳入无前列腺疾病的脱发成年男性,比较连续使用1mg非那雄胺≥3年或≥5年者与未用药对照。结果显示长期低剂量非那雄胺与良性前列腺增生(BPH)和前列腺癌(PCa)诊断风险降低相关,3年BPH风险比0.64、PCa风险比0.49,5年分别为0.52和0.47,绝对PCa诊断率仍低。
要点
- 长期低剂量非那雄胺与BPH诊断风险降低相关,3年HR 0.64,5年HR 0.52。
- 长期低剂量非那雄胺与前列腺癌诊断风险降低相关,3年HR 0.49,5年HR 0.47。
- 有症状和无症状BPH的结果模式一致,绝对前列腺癌诊断率仍低。
核心结论
- 在因脱发接受治疗的男性中,长期低剂量非那雄胺与 incident BPH 和 PCa 诊断减少相关。
研究设计与样本
- 回顾性队列研究,使用TriNetX Research Network数据。
- 纳入无既往BPH或PCa的雄激素性脱发或非瘢痕性脱发成年男性。
- 暴露组定义为连续使用1mg非那雄胺≥3年或≥5年,与未使用非那雄胺的脱发对照比较。
- 倾向性评分1:1匹配人口学、合并症、实验室、药物和医疗利用,3年队列每组6741例,5年队列每组4534例。
- 采用Kaplan-Meier和Cox模型进行时间-事件分析,主要指标为风险比(HR)。
主要发现
- 3年时,非那雄胺与BPH诊断风险降低相关(HR 0.64,95% CI 0.55-0.75)。
- 3年时,非那雄胺与PCa诊断风险降低相关(HR 0.49,95% CI 0.33-0.74)。
- 5年时,非那雄胺与BPH诊断风险降低相关(HR 0.52,95% CI 0.43-0.63)。
- 5年时,非那雄胺与PCa诊断风险降低相关(HR 0.47,95% CI 0.28-0.79)。
- 有症状和无症状BPH的模式一致,绝对PCa诊断率仍低。
临床怎么用
- 对于因脱发长期使用低剂量非那雄胺的男性,应知晓其BPH和PCa诊断风险可能较低。
- 临床决策中需结合个体情况,不能仅凭此观察性研究改变前列腺癌筛查策略。
局限性
- 回顾性观察性研究,可能存在残余混杂。
- 需要前瞻性研究阐明机制和长期临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between long-term finasteride use and incident benign prostatic hyperplasia (BPH) and prostate cancer (PCa) diagnosis. Low-dose finasteride (1 mg) is widely prescribed for androgenic alopecia, often via telemedicine, resulting in prolonged use in men without baseline prostatic disease. While higher-dose finasteride is studied for BPH and PCa prevention, urologic outcomes of chronic low-dose use remain unclear. METHODS: In this retrospective cohort study using the TriNetX Research Network, adult men with androgenic or nonscarring alopecia and no prior BPH or PCa were included. Exposure cohorts were defined by continuous finasteride 1 mg use for ≥3 or ≥5 years and compared to alopecia controls without finasteride. Cohorts were matched 1:1 via propensity scores for demographics, comorbidities, labs, medications, and healthcare utilization. Time-to-event analyses used Kaplan-Meier and Cox models, with hazard ratios (HRs) as the primary measure. RESULTS: After matching, 6741 patients per group comprised the 3-year cohort and 4534 per group the 5-year cohort. At three years, finasteride was associated with lower BPH (HR 0.64, 95% CI 0.55-0.75) and PCa diagnosis (HR 0.49, 95% CI 0.33-0.74). At five years, finasteride was associated with lower BPH (HR 0.52, 95% CI 0.43-0.63) and PCa diagnosis (HR 0.47, 95% CI 0.28-0.79). Patterns were consistent for symptomatic and asymptomatic BPH. Absolute PCa diagnosis rates remained low. CONCLUSIONS: In men treated for alopecia, long-term low-dose finasteride was associated with reduced incident BPH and PCa diagnosis. Prospective studies are needed to clarify mechanisms and long-term clinical implications.
引用
- Adler R, Kozlov M, Viola J, et al. The Risk of Benign Prostatic Hyperplasia and Prostate Cancer With Long-term, Low Dose Finasteride Use in Adult Men with Nonscarring Alopecia: A Propensity-matched Observational Study. Urology. 2026. PMID: 42034292. doi:10.1016/j.urology.2026.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。